A surprising complete radiographic response to palbociclib plus endocrine therapy in an HR-positive, HER2-low lung, pleural, and lymph node metastatic breast cancer patient: a case report
Hormone receptor-positive, human epidermal growth factor receptor 2-low (HER2-low) metastatic breast cancer (MBC) constitutes the predominant subtype of advanced breast cancer, with most patients eventually developing resistance to endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). This case r...